FDA Updates in Endocrinology


The end of the year brought many new FDA developments, including approval of a long-acting insulin and updated warnings for SGLT2 inhibitors.

Recent FDA news is outlined in the following slides.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.